<DOC>
	<DOCNO>NCT01266369</DOCNO>
	<brief_summary>The objective compare efficacy safety AB1010 3 6 mg/kg/day treatment patient mastocytosis handicap bearing activate point mutation phosphotransferase domain c-Kit main mutation Asp-816-Val ( D816V ) .</brief_summary>
	<brief_title>Masitinib Patients With Mastocytosis With Handicap Bearing D816V Mutation</brief_title>
	<detailed_description />
	<mesh_term>Mastocytosis</mesh_term>
	<criteria>1 . Patients one follow document mastocytosis : Smouldering systemic mastocytosis Indolent systemic mastocytosis organomegaly Indolent Systemic Mastocytosis 2 infiltrated organ ( skin bonemarrow ) Any mastocytosis last 6 month least 3 anaphylactic shock syncops require either use adrenaline medical assistance Cutaneous Mastocytosis ( CM ) 2 . Skin biopsydocumented mastocytosis evaluable disease base upon : Histological criterion : typical infiltrates mast cell multifocal diffuse pattern skin biopsy Clinical criterion : typical skin lesion ( maculopapular , urticaria pigmentosa , mastocytoma ) 3 . Missing data ( ckit molecular analysis do ) document presence activate point mutation phosphotransferase domain ckit D816V ckit mutation least one infiltrate organ ( bone marrow skin ) 4 . Refractory least one symptomatic treatment : Anti H1 Anti H2 Proton pump inhibitor Osteoclast inhibitor Cromoglycate Sodium Antileukotriene Other therapy use symptomatic care 5 . Handicap define least one follow handicap : pruritus score ≥ 6 number flush per week ≥ 7 number stool per day ≥ 4 , number mictions per day ≥ 8 , QLQC30 score ≥ 60 , Hamilton score ≥ 10 1 . Patients one follow mastocytosis : Systemic Mastocytosis Associated clonal Hematologic Non Mast cell lineage Disease ( SMAHNMD ) Mast cell leukemia ( MCL ) Aggressive systemic mastocytosis ( ASM ) 2 . Patient major surgery within 2 week prior study entry 3 . No vulnerable population include study Life expectancy &lt; 6 month . Patient &lt; 5 year free malignancy , except treat basal cell skin cancer cervical carcinoma situ . Patient grade III/IV cardiac problem define New York Heart Association Criteria . ( i.e. , congestive heart failure , myocardial infarction within 6 month study ) Patient severe and/or uncontrolled medical disease . Patient known diagnosis human immunodeficiency virus ( HIV ) infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>mastocytosis</keyword>
	<keyword>D816V</keyword>
	<keyword>handicap</keyword>
</DOC>